Skip to main content
HLB INC. logo

HLB INC. — Investor Relations & Filings

Ticker · 028300 ISIN · KR7028300002 LEI · 988400ZL885PLZG8E576 KO Manufacturing
Open in API
Filings indexed 555 across all filing types
Latest filing 2022-03-22 Audit Report / Informat…
Country KR South Korea
Listing KO 028300

About HLB INC.

https://www.hlb.global/

HLB INC. is a biopharmaceutical company focused on developing new global anti-cancer drugs. The company's core activities center on advancing a pipeline of novel therapeutics through its worldwide network, which includes subsidiaries like Elevar Therapeutics and Immunomic Therapeutics. In addition to its primary focus on oncology, HLB's affiliated companies are involved in other life science areas, such as developing and manufacturing in vitro diagnostic medical devices, peptide-based biomaterials, and quasi-drugs. The group also has operations in composite materials and shipbuilding, reflecting its diversified origins.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing from HLB titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion, financial highlights (assets, liabilities, profit/loss), and auditor information for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART system) confirming the receipt and submission of the audit report, rather than the full, multi-page audited financial statement document itself. Therefore, it fits the 'Report Publication Announcement' (RPA) category. FY 2021
2022-03-22 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for HLB Co., Ltd. for the fiscal year ending December 31, 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. Since this is a full annual financial report containing audited statements rather than just an earnings release or a summary, it is classified as an Annual Report (10-K). FY 2021
2022-03-22 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by HLB Co., Ltd. It details specific corrections made to financial statements (consolidated and separate) that were originally included in the proxy materials for the upcoming Annual General Meeting. Since the primary purpose of this document is to provide information to shareholders to solicit their votes for the AGM, it falls under the Proxy Solicitation category.
2022-03-22 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) for a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고). It details specific corrections made to the original notice, including financial statement data and director remuneration information. Since this document is a formal filing related to the materials and agenda for an upcoming Annual General Meeting (AGM), it falls under the AGM-R category.
2022-03-22 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific executives, including the number of shares, exercise price, vesting periods, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of share issuance or capital changes.
2022-03-14 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for HLB. It details the agenda items, including financial statement approval, director appointments, and business purpose changes. This document serves as the official notification and proxy information for shareholders to attend or vote at the upcoming Annual General Meeting. It fits the definition of Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to exercise their voting rights.
2022-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.